According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $1.82 B. In 2022 the company made a revenue of $1.03 B an increase over the years 2021 revenue that were of $0.84 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.82 B | 76.23% |
2022 | $1.03 B | 22.88% |
2021 | $0.84 B | 71.31% |
2020 | $0.49 B | 124.28% |
2019 | $0.21 B | 193.36% |
2018 | $74.9 M | -16.69% |
2017 | $89.91 M | 90.66% |
2016 | $47.15 M | 14.75% |
2015 | $41.09 M | -18.72% |
2014 | $50.56 M | 7.2% |
2013 | $47.16 M | -29.31% |
2012 | $66.72 M | -19.37% |
2011 | $82.75 M | -17.28% |
2010 | $0.10 B | -0.49% |
2009 | $0.10 B | 4.54% |
2008 | $96.16 M | 88.94% |
2007 | $50.89 M | 89% |
2006 | $26.93 M | 371.13% |
2005 | $5.71 M | 33.61% |
2004 | $4.27 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novartis NVS | $51.01 B | 2,690.15% | ๐จ๐ญ Switzerland |
Sanofi SNY | $50.35 B | 2,654.48% | ๐ซ๐ท France |
Regeneron Pharmaceuticals REGN | $13.11 B | 617.46% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | $1.24 B | -31.99% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | N/A | N/A | ๐บ๐ธ USA |
OPKO Health
OPK | $0.86 B | -52.77% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | 766.71% | ๐ฎ๐ฑ Israel |
Arrowhead Pharmaceuticals
ARWR | $0.18 B | -90.06% | ๐บ๐ธ USA |